{
    "organizations": [],
    "uuid": "b7bb08d0c7ce652ad60bc48f47baee8925da37f9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-magenta-therapeutics-and-heidelber/brief-magenta-therapeutics-and-heidelberg-pharma-sign-agreement-for-development-of-antibody-drug-conjugates-idUSFWN1QN0FT",
    "ord_in_thread": 0,
    "title": "BRIEF-Magenta Therapeutics And Heidelberg Pharma Sign Agreement For Development Of Antibody Drug Conjugates",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 5 (Reuters) - Heidelberg Pharma Ag:\n* MAGENTA THERAPEUTICS AND HEIDELBERG PHARMA SIGN EXCLUSIVE MULTI-TARGET RESEARCH AGREEMENT FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES\n* HEIDELBERG PHARMA AG - ‍MAGENTA WILL HAVE ACCESS TO CO’S AMANITIN TOXIN-LINKER PLATFORM TECHNOLOGY​\n* HEIDELBERG PHARMA AG -MAGENTA HAS OPTION FOR EXCLUSIVE TARGET-SPECIFIC LICENSE FOR GLOBAL DEVELOPMENT, COMMERCIALIZATION RIGHTS TO PRODUCT CANDIDATES\n* HEIDELBERG PHARMA AG - ‍CO TO RECEIVE UPFRONT TECHNOLOGY ACCESS, EXCLUSIVITY FEES, PAYMENTS FOR RESEARCH SUPPORT​\n* HEIDELBERG PHARMA - TO BE ELIGIBLE TO RECEIVE OPTION FEES, DEVELOPMENT, REGULATORY,SALES-RELATED MILESTONE PAYMENTS UP TO $334 MILLION, UNDER CONDITIONS​ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-03-05T22:36:00.000+02:00",
    "crawled": "2018-03-06T22:37:38.035+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "heidelberg",
        "pharma",
        "ag",
        "magenta",
        "therapeutic",
        "heidelberg",
        "pharma",
        "sign",
        "exclusive",
        "research",
        "agreement",
        "development",
        "antibody",
        "drug",
        "conjugate",
        "heidelberg",
        "pharma",
        "ag",
        "access",
        "co",
        "amanitin",
        "platform",
        "heidelberg",
        "pharma",
        "ag",
        "option",
        "exclusive",
        "license",
        "global",
        "development",
        "commercialization",
        "right",
        "product",
        "candidate",
        "heidelberg",
        "pharma",
        "ag",
        "receive",
        "upfront",
        "technology",
        "access",
        "exclusivity",
        "fee",
        "payment",
        "research",
        "heidelberg",
        "pharma",
        "eligible",
        "receive",
        "option",
        "fee",
        "development",
        "regulatory",
        "milestone",
        "payment",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}